JPRN-UMIN000002769已完成未知
Evaluation of cinacalcet on clinical outcome depending on serum PTH level in Japanese patients with SHPT:ECO study - Evaluation of cinacalcet on clinical outcome for in Japanese patients with SHPT:ECO study
Division of Kidney and Hypertension, Department of Internal Medicine,The Jikei University School of Medicine0 个研究点目标入组 120 人开始时间: 2009年11月18日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. pregnant woman 2.received therapy with bisphosphonate within 24 weeks before IC 3.received therapy with estrogen hormone when signed IC 4.severe hepatic dysfunction or cirrhosis 5. drug allergies 6. malignancy 7. unsuitable patients
研究者
相似试验
进行中（未招募）
不适用
Assess the stability / benefit of Cinacalcet treatment over conventional therapy based on bone metabolism, arterial stiffness and vascular calcification in advanced chronic renal failureBone's disorders and mineral metabolism and vascular involvementMedDRA version: 16.1Level: PTClassification code 10051753Term: Vascular calcificationSystem Organ Class: 10047065 - Vascular disordersEUCTR2013-002270-52-ESHospital Universitari de Girona Dr.Josep Trueta
已完成
4 期
Efficacy and safety of treatment with Cinacalcet in patients with Primary Hyperparathyroidism due to a MEN-1 mutatioprimary hyperparathyroidismhyperactive parathyroid glands1008362410033949NL-OMON34871eids Universitair Medisch Centrum20
已完成
不适用
Prospective Study on the effects of cinacalcet HCL on vascular calcification and parathyroid glands size in patients on maintenance hemodialysischronic kidney disease patients with hyperparathyroidism undergoing hemodialysisJPRN-UMIN000002628Division of Nephrology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine60
终止
3 期
Pediatric Chronic Kidney Disease Safety and EfficacyChronic Kidney DiseaseHyperparathyroidism, SecondarySecondary HyperparathyroidismKidney DiseaseHyperparathyroidismNCT01277510Amgen43
进行中（未招募）
不适用
Efficacy and safety of the calcimimetic Cinacalcet in the management of patients with Primary Hyperparathyroidism due to a MEN-1 mutation - Cinacalcet in MEN-I PHPTPatients with primary hyperparathyroidism due to a germline mutation in the MEN-1 geneMedDRA version: 12.1Level: LLTClassification code 10036693Term: Primary hyperparathyroidismEUCTR2010-018861-53-NLeiden University Medical Center